Showing results (1381-1390 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|March 27, 2007
Evaluation of ABT-751 against childhood cancer models in vivoChristopher L Morton, Edward G Favours, Kimberly S Mercer, et al.
Investigational New Drugs|February 8, 2007
Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantroneEnnio Cavalletti, Luca Crippa, Patrizia Mainardi, et al.
Investigational New Drugs|September 14, 2006
Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancerJehana James, Daryl J Murry, Anthony M Treston, et al.
Investigational New Drugs|May 1, 1991
Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot studyC P Steuber, T Holbrook, B Camitta, et al.
Investigational New Drugs|July 22, 2005
Growth inhibition and apoptosis-induced effect on human cancer cells of toosendanin, a triterpenoid derivative from chinese traditional medicineBin Zhang, Zhong-Feng Wang, Mian-Zhi Tang, et al.
Investigational New Drugs|July 22, 2005
Phase II study of perifosine in previously untreated patients with metastatic melanomaD Scott Ernst, Elizabeth Eisenhauer, Nancy Wainman, et al.
Investigational New Drugs|April 19, 2007
Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitroElin Lindhagen, Linda Rickardson, Gary Elliott, et al.
Investigational New Drugs|March 30, 2007
Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)Jennifer J Knox, Sebastien J Hotte, Christian Kollmannsberger, et al.
Investigational New Drugs|April 27, 2007
Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathwayPavel Krejci, Katerina Pejchalova, William R Wilcox
Investigational New Drugs|April 27, 2007
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)Charles J Ryan, Walter M Stadler, Bruce Roth, et al.
Pageof 372